Parthenolide suppresses tumor growth in a xenograft model of colorectal cancer cells by inducing mitochondrial dysfunction and apoptosis

International Journal of Oncology

Volumn 41, Issue 4, 2012, Pages 1547-1553

  Kim, Se Lim ^a   Trang, Kieu The Thu ^a   Kim, Seong Hun ^a   Kim, In Hee ^a   Lee, Seung Ok ^a   Lee, Soo Teik ^a   Kim, Dae Ghon ^a   Kim, Sang Wook ^a  

^a Chonbuk National University Medical School   (South Korea)

Author keywords

Anti tumor effect; Colorectal cancer; Mitochondrial dysfunction; Parthenolide

Indexed keywords

CASPASE 3; CYTOCHROME C; PARTHENOLIDE; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT;

APOPTOSIS; CARCINOGENESIS; COLORECTAL NEOPLASMS; CYTOCHROMES C; GENES, BCL-2; HT29 CELLS; HUMANS; MITOCHONDRIA; NEOVASCULARIZATION, PATHOLOGIC; SESQUITERPENES; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866480747     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1587     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Meyerhardt JA and Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med 352: 476-487, 2005.
3. Tebbutt NC, Cattell E, Midgley R, Cunningham D and Kerr D: Systemic treatment of colorectal cancer. Eur J Cancer 38: 1000-1015, 2002.
4. Gusella M, Frigo AC, Bolzonella C, et al: Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. Br J Cancer 100: 1549-1557, 2009.
5. Raymond E, Faivre S, Chaney S, Woynarowski J and Cvitkovic E: Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1: 227-235, 2002.
6. Knight DW: Feverfew: chemistry and biological activity. Nat Prod Rep 12: 271-276, 1995.
7. Murphy JJ, Heptinstall S and Mitchell JR: Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 2: 189-192, 1988.
8. Hehner SP, Heinrich M, Bork PM, et al: Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta. J Biol Chem 273: 1288-1297, 1998.
9. Lyss G, Knorre A, Schmidt TJ, Pahl HL and Merfort I: The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-kappaB by directly targeting p65. J Biol Chem 273: 33508-33516, 1998.
10. Zhang S, Ong CN and Shen HM: Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer Lett 208: 143-153, 2004.
11. Wen J, You KR, Lee SY, Song CH and Kim DG: Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J Biol Chem 277: 38954-38964, 2002.
12. Pajak B, Gajkowska B and Orzechowski A: Molecular basis of parthenolide-dependent proapoptotic activity in cancer cells. Folia Histochem Cytobiol 46: 129-135, 2008.
13. Mathema VB, Koh YS, Thakuri BC and Sillanpaa M: Parthenolide, a sesquiterpene lactone, expresses multiple anti-cancer and antiinflammatory activities. Inflammation 35: 560-565, 2012.
14. Zhao LJ, Xu YH and Li Y: Effect of parthenolide on proliferation and apoptosis in gastric cancer cell line SGC7901. J Dig Dis 10: 172-180, 2009.
15. Zhang S, Ong CN and Shen HM: Involvement of proapoptotic Bcl-2 family members in parthenolide-induced mitochondrial dysfunction and apoptosis. Cancer Lett 211: 175-188, 2004.
16. Chen YC, Shen SC, Lee WR, et al: Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production. Biochem Pharmacol 64: 1713-1724, 2002.
17. Grutter MG: Caspases: key players in programmed cell death. Curr Opin Struct Biol 10: 649-655, 2000.
18. Yang JC and Cortopassi GA: Induction of the mitochondrial permeability transition causes release of the apoptogenic factor cytochrome c. Free Radic Biol Med 24: 624-631, 1998.
19. Tacchini L, De Ponti C, Matteucci E, Follis R and Desiderio MA: Hepatocyte growth factor-activated NF-kappaB regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines. Carcinogenesis 25: 2089-2100, 2004.
20. Dai Y, Guzman ML, Chen S, et al: The NF (nuclear factor)-kappaB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. Br J Haematol 151: 70-83, 2010.
21. Nakshatri H, Rice SE and Bhat-Nakshatri P: Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 23: 7330-7344, 2004.
22. Carlisi D, D'Anneo A, Angileri L, et al: Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation. J Cell Physiol 226: 1632-1641, 2011.
23. Chen KF, Tai WT, Liu TH, et al: Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res 16: 5189-5199, 2010.
24. Wu C, Chen F, Rushing JW, et al: Antiproliferative activities of parthenolide and golden feverfew extract against three human cancer cell lines. J Med Food 9: 55-61, 2006.
25. Fernandes-Alnemri T, Litwack G and Alnemri ES: CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem 269: 30761-30764, 1994.
26. Mehmet H: Caspases find a new place to hide. Nature 403: 29-30, 2000.
27. Yang E and Korsmeyer SJ: Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 88: 386-401, 1996.
28. Green DR and Reed JC: Mitochondria and apoptosis. Science 281: 1309-1312, 1998.
29. Reed JC: Double identity for proteins of the Bcl-2 family. Nature 387: 773-776, 1997.
30. Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326, 1998.
31. Gross A, McDonnell JM and Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13: 1899-1911, 1999.
32. Terrones O, Antonsson B, Yamaguchi H, et al: Lipidic pore formation by the concerted action of proapoptotic BAX and tBID. J Biol Chem 279: 30081-30091, 2004.
33. Van Mau N, Kajava AV, Bonfils C, Martinou JC and Harricane MC: Interactions of Bax and tBid with lipid monolayers. J Membr Biol 207: 1-9, 2005.
34. Coutts AS and La Thangue N: The p53 response during DNA damage: impact of transcriptional cofactors. Biochem Soc Symp pp181-189, 2006.
35. Kroemer G and Reed JC: Mitochondrial control of cell death. Nat Med 6: 513-519, 2000.
36. Borner C: The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol 39: 615-647, 2003.
37. Ferrara N, Hillan KJ, Gerber HP and Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391-400, 2004.
38. Huang S, Pettaway CA, Uehara H, Bucana CD and Fidler IJ: Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20: 4188-4197, 2001.
39. Oka D, Nishimura K, Shiba M, et al: Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappaB. Int J Cancer 120: 2576-2581, 2007.
40. Weng SX, Sui MH, Chen S, et al: Parthenolide inhibits proliferation of vascular smooth muscle cells through induction of G0/G1 phase cell cycle arrest. J Zhejiang Univ Sci B 10: 528-535, 2009.